LJPC-501: Ph III ATHOS-3 data

Top-line data from 321 critically ill patients with catecholamine-resistant hypotension on a background of standard-of-care vasopressors in the double-blind, international Phase III ATHOS-3 trial showed that continuous treatment with dose-titrated IV LJPC-501 for up to 7 days met the primary endpoint of improving the rate of blood pressure response vs. placebo (70% vs. 23%, p<0.00001).

Response was defined as a mean arterial pressure of ≥75 mmHg or a 10 mmHg improvement from baseline pressure at 3 hours following the start of treatment without increasing vasopressors. ...